<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38020714</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2688-2663</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>MedComm</Title><ISOAbbreviation>MedComm (2020)</ISOAbbreviation></Journal><ArticleTitle>Blood-derived product therapies for SARS-CoV-2 infection and long COVID.</ArticleTitle><Pagination><StartPage>e426</StartPage><MedlinePgn>e426</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e426</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/mco2.426</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is capable of large-scale transmission and has caused the coronavirus disease 2019 (COVID-19) pandemic. Patients with COVID-19 may experience persistent long-term health issues, known as long COVID. Both acute SARS-CoV-2 infection and long COVID have resulted in persistent negative impacts on global public health. The effective application and development of blood-derived products are important strategies to combat the serious damage caused by COVID-19. Since the emergence of COVID-19, various blood-derived products that target or do not target SARS-CoV-2 have been investigated for therapeutic applications. SARS-CoV-2-targeting blood-derived products, including COVID-19 convalescent plasma, COVID-19 hyperimmune globulin, and recombinant anti-SARS-CoV-2 neutralizing immunoglobulin G, are virus-targeting and can provide immediate control of viral infection in the short term. Non-SARS-CoV-2-targeting blood-derived products, including intravenous immunoglobulin and human serum albumin exhibit anti-inflammatory, immunomodulatory, antioxidant, and anticoagulatory properties. Rational use of these products can be beneficial to patients with SARS-CoV-2 infection or long COVID. With evidence accumulated since the pandemic began, we here summarize the progress of blood-derived product therapies for COVID-19, discuss the effective methods and scenarios regarding these therapies, and provide guidance and suggestions for clinical treatment.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. MedComm published by Sichuan International Medical Exchange &amp; Promotion Association (SCIMEA) and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Junzheng</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8500-1907</Identifier><AffiliationInfo><Affiliation>Chengdu Rongsheng Pharmaceuticals Co., Ltd. Chengdu China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Huichuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>China National Biotec Group Company Ltd Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Ding</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Chengdu Rongsheng Pharmaceuticals Co., Ltd. Chengdu China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Tiantan Biological Products Co., Ltd. Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-2598-4355</Identifier><AffiliationInfo><Affiliation>China National Biotec Group Company Ltd Beijing China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>MedComm (2020)</MedlineTA><NlmUniqueID>101769925</NlmUniqueID><ISSNLinking>2688-2663</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2 infection</Keyword><Keyword MajorTopicYN="N">anti&#x2010;inflammatory</Keyword><Keyword MajorTopicYN="N">blood&#x2010;derived products</Keyword><Keyword MajorTopicYN="N">immunomodulatory</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">passive immunotherapy</Keyword></KeywordList><CoiStatement>J. Z. W. and D. Y. are paid employees of Chengdu Rongsheng Pharmaceuticals Co., Ltd. D. Y. is an employee of Beijing Tiantan Biological Products Co., Ltd. H. C. Y. and X. M. Y. are paid employees of China National Biotec Group Company Ltd (CNBG). These companies are involved in the development of COVID&#x2010;HIG; CNBG is involved in the development of anti&#x2010;SARS&#x2010;CoV&#x2010;2 neutralizing IgG (recombinant). The views presented here should not be considered endorsements of any specific products or company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>14</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38020714</ArticleId><ArticleId IdType="pmc">PMC10651828</ArticleId><ArticleId IdType="doi">10.1002/mco2.426</ArticleId><ArticleId IdType="pii">MCO2426</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
World Health Organization
. WHO coronavirus (COVID&#x2010;19) dashboard. 2023 Accessed March 25, https://covid19.who.int/; 2023.</Citation></Reference><Reference><Citation>
World Health Organization
. Tracking SARS&#x2010;CoV&#x2010;2 variants. 2023. Accessed October 2, 2023. https://www.who.int/activities/tracking&#x2010;SARS&#x2010;CoV&#x2010;2&#x2010;variants
</Citation></Reference><Reference><Citation>Lobinska G, Pauzner A, Traulsen A, Pilpel Y, Nowak MA. Evolution of resistance to COVID&#x2010;19 vaccination with dynamic social distancing. Nat Hum Behav. 2022;6(2):193&#x2010;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">35210582</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki A, Lion S, Boots M. Antigenic escape selects for the evolution of higher pathogen transmission and virulence. Nat Ecol Evol. 2022;6(1):51&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671278</ArticleId><ArticleId IdType="pubmed">34949816</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli AM, Peacock TP, Thorne LG, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21(3):162&#x2010;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg T, Ferguson NM, Nash SG, et&#xa0;al. Comparative analysis of the risks of hospitalisation and death associated with SARS&#x2010;CoV&#x2010;2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303&#x2010;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID&#x2010;19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2010;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2010;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al&#x2010;Aly Z. Postacute sequelae of COVID&#x2010;19 at 2 years. Nat Med. 2023;29(9):2347&#x2010;2357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson LA, Canna SW, Friedman KG, et&#xa0;al. American college of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS&#x2010;CoV&#x2010;2 and hyperinflammation in pediatric COVID&#x2010;19: version 1. Arthritis Rheumatol. 2020;72(11):1791&#x2010;1805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405113</ArticleId><ArticleId IdType="pubmed">32705809</ArticleId></ArticleIdList></Reference><Reference><Citation>
United States Food and Drug Administration
. Emergency use authorization. 2023. Accessed March 25, 2023; https://www.fda.gov/emergency&#x2010;preparedness&#x2010;and&#x2010;response/mcm&#x2010;legal&#x2010;regulatory&#x2010;and&#x2010;policy&#x2010;framework/emergency&#x2010;use&#x2010;authorization
</Citation></Reference><Reference><Citation>Montalvo M, Nallapaneni P, Hassan S, et&#xa0;al. Autoimmune gastrointestinal dysmotility following SARS&#x2010;CoV&#x2010;2 infection successfully treated with intravenous immunoglobulin. Neurogastroenterol Motil. 2022;34(7):e14314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9257846</ArticleId><ArticleId IdType="pubmed">34984765</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization
. Blood products. 2023. Accessed October 2, 2023; https://www.who.int/health&#x2010;topics/blood&#x2010;products#tab=tab_1
</Citation></Reference><Reference><Citation>RECOVERY Collaborative Group . Convalescent plasma in patients admitted to hospital with COVID&#x2010;19 (RECOVERY): a randomised controlled, open&#x2010;label, platform trial. Lancet. 2021;397(10289):2049&#x2010;2059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8121538</ArticleId><ArticleId IdType="pubmed">34000257</ArticleId></ArticleIdList></Reference><Reference><Citation>ITAC (INSIGHT 013) Study Group . Hyperimmune immunoglobulin for hospitalised patients with COVID&#x2010;19 (ITAC): a double&#x2010;blind, placebo&#x2010;controlled, phase 3, randomised trial. Lancet. 2022;399(10324):530&#x2010;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8797010</ArticleId><ArticleId IdType="pubmed">35093205</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan DJ, Gebo KA, Shoham S, et&#xa0;al. Early outpatient treatment for Covid&#x2010;19 with convalescent plasma. N Engl J Med. 2022;386(18):1700&#x2010;1711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006786</ArticleId><ArticleId IdType="pubmed">35353960</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Yu W, Zhao Y, et&#xa0;al. Albumin infusion may improve the prognosis of critical COVID&#x2010;19 patients with hypoalbuminemia in the intensive care unit: a retrospective cohort study. Infect Drug Resist. 2022;15:6039&#x2010;6050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9579967</ArticleId><ArticleId IdType="pubmed">36277241</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID&#x2010;19: progress and lessons learned. Nat Rev Drug Discov. 2023;22(6):449&#x2010;475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10113999</ArticleId><ArticleId IdType="pubmed">37076602</ArticleId></ArticleIdList></Reference><Reference><Citation>Toussi SS, Hammond JL, Gerstenberger BS, Anderson AS. Therapeutics for COVID&#x2010;19. Nat Microbiol. 2023;8(5):771&#x2010;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">37142688</ArticleId></ArticleIdList></Reference><Reference><Citation>Meganck RM, Baric RS. Developing therapeutic approaches for twenty&#x2010;first&#x2010;century emerging infectious viral diseases. Nat Med. 2021;27(3):401&#x2010;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">33723456</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu D, Kulkarni R. Overview of blood components and their preparation. Indian J Anaesth. 2014;58(5):529&#x2010;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4260297</ArticleId><ArticleId IdType="pubmed">25535413</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuckfield A, Haeusler MN, Grigg AP, Metz J. Reduction of inappropriate use of blood products by prospective monitoring of transfusion request forms. Med J Aust. 1997;167(9):473&#x2010;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">9397061</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzik WH, Blajchman MA, Fergusson D, et&#xa0;al. Clinical review: Canadian National Advisory Committee on Blood and Blood Products&#x2013;Massive transfusion consensus conference 2011: report of the panel. Crit Care. 2011;15(6):242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388668</ArticleId><ArticleId IdType="pubmed">22188866</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin RJ, McLaughlin LS. Plasma components: properties, differences, and uses. Transfusion. 2012;52:9S&#x2010;19S. Suppl 1.</Citation><ArticleIdList><ArticleId IdType="pubmed">22578375</ArticleId></ArticleIdList></Reference><Reference><Citation>Grazzini G, Mannucci PM, Oleari F. Plasma&#x2010;derived medicinal products: demand and clinical use. Blood Transfus. 2013;11(4):s2&#x2010;s5. Suppl 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853983</ArticleId><ArticleId IdType="pubmed">24333309</ArticleId></ArticleIdList></Reference><Reference><Citation>Strengers PFW. Challenges for plasma&#x2010;derived medicinal products. Transfus Med Hemother. 2023;50(2):116&#x2010;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10091012</ArticleId><ArticleId IdType="pubmed">37066053</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JS, Warrington R, Watson W, Kim HL. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. 2018;14(2):49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6156898</ArticleId><ArticleId IdType="pubmed">30263032</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID&#x2010;19. Lancet Infect Dis. 2020;20(4):398&#x2010;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128218</ArticleId><ArticleId IdType="pubmed">32113510</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Health Commission of the People's Republic of China. Diagnosis and treatment protocol for COVID&#x2010;19 (Trial version 4). 2020. Accessed March 25, 2023. http://www.gov.cn/zhengce/zhengceku/2020&#x2010;01/28/content_5472673.htm
</Citation></Reference><Reference><Citation>Duan K, Liu B, Li C, et&#xa0;al. Effectiveness of convalescent plasma therapy in severe COVID&#x2010;19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490&#x2010;9496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196837</ArticleId><ArticleId IdType="pubmed">32253318</ArticleId></ArticleIdList></Reference><Reference><Citation>
United States Food and Drug Administration
. CCP EUA_LOA Final 12 27 2021. With appendix from February 9, 2022. 2021. Accessed March 25, 2023. https://www.fda.gov/media/141477/download
</Citation></Reference><Reference><Citation>
National Health Commission of the People's Republic of China
. Diagnosis and treatment protocol for COVID&#x2010;19 (trial version 9). 2022. Accessed March 25, 2023. http://www.gov.cn/xinwen/2022&#x2010;06/28/content_5698168.htm
</Citation></Reference><Reference><Citation>
National Health Commission of the People's Republic of China
. Diagnosis and treatment protocol for COVID&#x2010;19 (trial version 8). 2021. Accessed March 25, 2023. http://www.gov.cn/zhengce/zhengceku/2021&#x2010;04/15/content_5599795.htm
</Citation></Reference><Reference><Citation>Vandeberg P, Cruz M, Diez JM, et&#xa0;al. Production of anti&#x2010;SARS&#x2010;CoV&#x2010;2 hyperimmune globulin from convalescent plasma. Transfusion. 2021;61(6):1705&#x2010;1709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8251388</ArticleId><ArticleId IdType="pubmed">33715160</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu D, Li YF, Liang H, et&#xa0;al. Potent anti&#x2010;SARS&#x2010;CoV&#x2010;2 efficacy of COVID&#x2010;19 hyperimmune globulin from vaccine&#x2010;immunized plasma. Adv Sci (Weinh). 2022;9(14):e2104333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9108634</ArticleId><ArticleId IdType="pubmed">35403837</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopardo G, Belloso WH, Nannini E, et&#xa0;al. RBD&#x2010;specific polyclonal F(ab&#xb4;)(2) fragments of equine antibodies in patients with moderate to severe COVID&#x2010;19 disease: a randomized, multicenter, double&#x2010;blind, placebo&#x2010;controlled, adaptive phase 2/3 clinical trial. EClinicalMedicine. 2021;34:100843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8037439</ArticleId><ArticleId IdType="pubmed">33870149</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Jian F, Zhang Z, et&#xa0;al. Rational identification of potent and broad sarbecovirus&#x2010;neutralizing antibody cocktails from SARS convalescents. Cell Rep. 2022;41(12):111845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9712074</ArticleId><ArticleId IdType="pubmed">36493787</ArticleId></ArticleIdList></Reference><Reference><Citation>Copin R, Baum A, Wloga E, et&#xa0;al. The monoclonal antibody combination REGEN&#x2010;COV protects against SARS&#x2010;CoV&#x2010;2 mutational escape in preclinical and human studies. Cell. 2021;184(15):3949&#x2010;3961. e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8179113</ArticleId><ArticleId IdType="pubmed">34161776</ArticleId></ArticleIdList></Reference><Reference><Citation>Alagheband Bahrami A, Azargoonjahromi A, Sadraei S, et&#xa0;al. An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID&#x2010;19). Cell Mol Biol Lett. 2022;27(1):38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9100302</ArticleId><ArticleId IdType="pubmed">35562685</ArticleId></ArticleIdList></Reference><Reference><Citation>
Foo United, AdministrationDrug
. FDA takes action on updated mRNA COVID&#x2010;19 vaccines to better protect against currently circulating variants. 2023. Accessed September 15, 2023. https://www.fda.gov/news&#x2010;events/press&#x2010;announcements/fda&#x2010;takes&#x2010;action&#x2010;updated&#x2010;mrna&#x2010;covid&#x2010;19&#x2010;vaccines&#x2010;better&#x2010;protect&#x2010;against&#x2010;currently&#x2010;circulating
</Citation></Reference><Reference><Citation>
PR Newswire
. China approves the world's first vaccine against XBB descendent lineages of SARS&#x2010;CoV&#x2010;2 for emergency use. 2023. Accessed August 23, 2023. https://www.prnewswire.com/news&#x2010;releases/china&#x2010;approves&#x2010;the&#x2010;worlds&#x2010;first&#x2010;vaccine&#x2010;against&#x2010;xbb&#x2010;descendent&#x2010;lineages&#x2010;of&#x2010;sars&#x2010;cov&#x2010;2&#x2010;for&#x2010;emergency&#x2010;use&#x2010;301846845.html
</Citation></Reference><Reference><Citation>He C, Alu A, Lei H, et&#xa0;al. A recombinant spike&#x2010;XBB.1.5 protein vaccine induces broad&#x2010;spectrum immune responses against XBB.1.5&#x2010;included Omicron variants of SARS&#x2010;CoV&#x2010;2. MedComm. 2023;4(3):e263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10133731</ArticleId><ArticleId IdType="pubmed">37125241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ao D, Lan T, He X, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 Omicron variant: immune escape and vaccine development. MedComm. 2022;3(1):e126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8925644</ArticleId><ArticleId IdType="pubmed">35317190</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Health Commission of the People's Republic of China
. Diagnosis and treatment protocol for COVID&#x2010;19 (Trial version 7). 2020. Accessed March 25, 2023. http://www.gov.cn/zhengce/zhengceku/2020&#x2010;03/04/content_5486705.htm
</Citation></Reference><Reference><Citation>
Centers for Disease Control and Prevention
. For parents: multisystem inflammatory syndrome in children (MIS&#x2010;C) associated with COVID&#x2010;19. 2023. Accessed August 23, 2023. https://www.cdc.gov/mis/mis&#x2010;c.html
</Citation></Reference><Reference><Citation>Evans L, Rhodes A, Alhazzani W, et&#xa0;al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181&#x2010;1247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8486643</ArticleId><ArticleId IdType="pubmed">34599691</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhazzani W, M&#xf8;ller MH, Arabi YM, et&#xa0;al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID&#x2010;19). Intensive Care Med. 2020;46(5):854&#x2010;887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101866</ArticleId><ArticleId IdType="pubmed">32222812</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramadori G. Albumin infusion in critically ill COVID&#x2010;19 patients: hemodilution and anticoagulation. Int J Mol Sci. 2021;22(13):7126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8268290</ArticleId><ArticleId IdType="pubmed">34281177</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Cheng A, Kumar R, et&#xa0;al. Hypoalbuminemia predicts the outcome of COVID&#x2010;19 independent of age and co&#x2010;morbidity. J Med Virol. 2020;92(10):2152&#x2010;2158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273060</ArticleId><ArticleId IdType="pubmed">32406952</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S, Li W, Shi X, et&#xa0;al. 3044 Cases reveal important prognosis signatures of COVID&#x2010;19 patients. Comput Struct Biotechnol J. 2021;19:1163&#x2010;1175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7870437</ArticleId><ArticleId IdType="pubmed">33584997</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu MA, Fossali T, Pandolfi L, et&#xa0;al. Hypoalbuminemia in COVID&#x2010;19: assessing the hypothesis for underlying pulmonary capillary leakage. J Intern Med. 2021;289(6):861&#x2010;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">33411411</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, et&#xa0;al. Immunoglobulin signature predicts risk of post&#x2010;acute COVID&#x2010;19 syndrome. Nat Commun. 2022;13(1):446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et&#xa0;al. Multiple early factors anticipate post&#x2010;acute COVID&#x2010;19 sequelae. Cell. 2022;185(5):881&#x2010;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Farcet MR, Karbiener M, Schwaiger J, Ilk R, Kreil TR. Rapidly increasing severe acute respiratory syndrome coronavirus 2 neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic. J Infect Dis. 2022;226(8):1357&#x2010;1361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989343</ArticleId><ArticleId IdType="pubmed">33725725</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero C, D&#xed;ez JM, Gajardo R. Anti&#x2010;SARS&#x2010;CoV&#x2010;2 antibodies in healthy donor plasma pools and IVIG products. Lancet Infect Dis. 2021;21(6):765&#x2010;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906732</ArticleId><ArticleId IdType="pubmed">33606999</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas&#x2010;Hill Z, et&#xa0;al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post&#x2010;acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76(3):e487&#x2010;e490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>
Montana Legislative Services. 2023 Montana Legislature.
. 2023. Accessed May 2, 2023. https://leg.mt.gov/bills/2023/billhtml/HB0645.htm
</Citation></Reference><Reference><Citation>Covington ML, Voma C, Stowell SR. Shortage of plasma&#x2010;derived products: a looming crisis? Blood. 2022;139(21):3222&#x2010;3225.</Citation><ArticleIdList><ArticleId IdType="pubmed">35259239</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanworth SJ, New HV, Apelseth TO, et&#xa0;al. Effects of the COVID&#x2010;19 pandemic on supply and use of blood for transfusion. Lancet Haematol. 2020;7(10):e756&#x2010;e764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7333996</ArticleId><ArticleId IdType="pubmed">32628911</ArticleId></ArticleIdList></Reference><Reference><Citation>
United States Food and Drug Administration
. Fractionated plasma products. Accessed October 2, 2023; 2019. https://www.fda.gov/vaccines&#x2010;blood&#x2010;biologics/approved&#x2010;blood&#x2010;products/fractionated&#x2010;plasma&#x2010;products
</Citation></Reference><Reference><Citation>Wu J, Zhang H, Lian T, et&#xa0;al. Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model. Biochem Biophys Res Commun. 2023;640:80&#x2010;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">36502635</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A, Pirofski LA. The convalescent sera option for containing COVID&#x2010;19. J Clin Invest. 2020;130(4):1545&#x2010;1548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108922</ArticleId><ArticleId IdType="pubmed">32167489</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter N, Wesche N, Perner A. The majority of patients in septic shock are transfused with fresh&#x2010;frozen plasma. Dan Med J. 2013;60(4):A4606.</Citation><ArticleIdList><ArticleId IdType="pubmed">23651716</ArticleId></ArticleIdList></Reference><Reference><Citation>Roback JD, Guarner J. Convalescent plasma to treat COVID&#x2010;19: possibilities and challenges. Jama. 2020;323(16):1561&#x2010;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">32219429</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Liu S, Liu J, et&#xa0;al. COVID&#x2010;19: immunopathogenesis and immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381863</ArticleId><ArticleId IdType="pubmed">32712629</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A, Joyner MJ, Pirofski LA. A randomized trial of convalescent plasma for COVID&#x2010;19&#x2010;potentially hopeful signals. Jama. 2020;324(5):455&#x2010;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">32492105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Deng Y, Zhao Z, et&#xa0;al. Characterization of SARS&#x2010;CoV&#x2010;2&#x2010;specific humoral immunity and its potential applications and therapeutic prospects. Cell Mol Immunol. 2022;19(2):150&#x2010;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8513558</ArticleId><ArticleId IdType="pubmed">34645940</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Li X, Zhang L, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7(1):141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047469</ArticleId><ArticleId IdType="pubmed">35484110</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaugel&#x2010;Novoa M, Bourlet T, Paul S. Role of the humoral immune response during COVID&#x2010;19: guilty or not guilty? Mucosal Immunol. 2022;15(6):1170&#x2010;1180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9530436</ArticleId><ArticleId IdType="pubmed">36195658</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang H, Nian X, Wu J, et&#xa0;al. COVID&#x2010;19 vaccination boosts the potency and breadth of the immune response against SARS&#x2010;CoV&#x2010;2 among recovered patients in Wuhan. Cell Discov. 2022;8(1):131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9734167</ArticleId><ArticleId IdType="pubmed">36494338</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhao X, Zhou H, et&#xa0;al. Broadly neutralizing antibodies to SARS&#x2010;CoV&#x2010;2 and other human coronaviruses. Nat Rev Immunol. 2023;23(3):189&#x2010;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9514166</ArticleId><ArticleId IdType="pubmed">36168054</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H, Zeng W, He H, et&#xa0;al. Serum IgA, IgM, and IgG responses in COVID&#x2010;19. Cell Mol Immunol. 2020;17(7):773&#x2010;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7331804</ArticleId><ArticleId IdType="pubmed">32467617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterlin D, Mathian A, Miyara M, et&#xa0;al. IgA dominates the early neutralizing antibody response to SARS&#x2010;CoV&#x2010;2. Sci Transl Med. 2021;13(577):eabd2223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857408</ArticleId><ArticleId IdType="pubmed">33288662</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q&#x2010;X, Liu B&#x2010;Z, Deng H&#x2010;J, et&#xa0;al. Antibody responses to SARS&#x2010;CoV&#x2010;2 in patients with COVID&#x2010;19. Nat Med. 2020;26(6):845&#x2010;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">32350462</ArticleId></ArticleIdList></Reference><Reference><Citation>Isho B, Abe KT, Zuo M, et&#xa0;al. Persistence of serum and saliva antibody responses to SARS&#x2010;CoV&#x2010;2 spike antigens in COVID&#x2010;19 patients. Sci Immunol. 2020;5(52):eabe5511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8050884</ArticleId><ArticleId IdType="pubmed">33033173</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;ez JM, Romero C, Cruz M, et&#xa0;al. Anti&#x2010;severe acute respiratory syndrome coronavirus 2 hyperimmune immunoglobulin demonstrates potent neutralization and antibody&#x2010;dependent cellular cytotoxicity and phagocytosis through N and S proteins. J Infect Dis. 2022;225(6):938&#x2010;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8574314</ArticleId><ArticleId IdType="pubmed">34693968</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang A, Stacey HD, D'Agostino MR, Tugg Y, Marzok A, Miller MS. Beyond neutralization: fc&#x2010;dependent antibody effector functions in SARS&#x2010;CoV&#x2010;2 infection. Nat Rev Immunol. 2023;23(6):381&#x2010;396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9761659</ArticleId><ArticleId IdType="pubmed">36536068</ArticleId></ArticleIdList></Reference><Reference><Citation>Redpath S, Michaelsen TE, Sandlie I, Clark MR. The influence of the hinge region length in binding of human IgG to human Fcgamma receptors. Hum Immunol. 1998;59(11):720&#x2010;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">9796740</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournazos S, Ravetch JV. Fc&#x3b3; receptor pathways during active and passive immunization. Immunol Rev. 2015;268(1):88&#x2010;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556827</ArticleId><ArticleId IdType="pubmed">26497515</ArticleId></ArticleIdList></Reference><Reference><Citation>Zohar T, Alter G. Dissecting antibody&#x2010;mediated protection against SARS&#x2010;CoV&#x2010;2. Nat Rev Immunol. 2020;20(7):392&#x2010;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7278217</ArticleId><ArticleId IdType="pubmed">32514035</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay MZ, Poh CM, R&#xe9;nia L, MacAry PA, Ng LFP. The trinity of COVID&#x2010;19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363&#x2010;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeniji OS, Giron LB, Purwar M, et&#xa0;al. COVID&#x2010;19 severity is associated with differential antibody fc&#x2010;mediated innate immune functions. mBio. 2021;12(2):e00281&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092230</ArticleId><ArticleId IdType="pubmed">33879594</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartsch YC, Wang C, Zohar T, et&#xa0;al. Humoral signatures of protective and pathological SARS&#x2010;CoV&#x2010;2 infection in children. Nat Med. 2021;27(3):454&#x2010;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8315827</ArticleId><ArticleId IdType="pubmed">33589825</ArticleId></ArticleIdList></Reference><Reference><Citation>Consiglio CR, Cotugno N, Sardh F, et&#xa0;al. The immunology of multisystem inflammatory syndrome in children with COVID&#x2010;19. Cell. 2020;183(4):968&#x2010;981. e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7474869</ArticleId><ArticleId IdType="pubmed">32966765</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C, Crespo &#xc2;, Ranjbar S, et&#xa0;al. Fc&#x3b3;R&#x2010;mediated SARS&#x2010;CoV&#x2010;2 infection of monocytes activates inflammation. Nature. 2022;606(7914):576&#x2010;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10071495</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId></ArticleIdList></Reference><Reference><Citation>Java A, Apicelli AJ, Liszewski MK, et&#xa0;al. The complement system in COVID&#x2010;19: friend and foe? JCI Insight. 2020;5(15):e140711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455060</ArticleId><ArticleId IdType="pubmed">32554923</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Liu L, Zhang Y, et&#xa0;al. High level of neutrophil extracellular traps correlates with poor prognosis of severe influenza A infection. J Infect Dis. 2018;217(3):428&#x2010;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">29325098</ArticleId></ArticleIdList></Reference><Reference><Citation>Veras FP, Pontelli MC, Silva CM, et&#xa0;al. SARS&#x2010;CoV&#x2010;2&#x2010;triggered neutrophil extracellular traps mediate COVID&#x2010;19 pathology. J Exp Med. 2020;217(12):e20201129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488868</ArticleId><ArticleId IdType="pubmed">32926098</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan C, Ma Z, Xie J, et&#xa0;al. The role of cell death in SARS&#x2010;CoV&#x2010;2 infection. Signal Transduct Target Ther. 2023;8(1):357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10509267</ArticleId><ArticleId IdType="pubmed">37726282</ArticleId></ArticleIdList></Reference><Reference><Citation>Laforge M, Elbim C, Fr&#xe8;re C, et&#xa0;al. Tissue damage from neutrophil&#x2010;induced oxidative stress in COVID&#x2010;19. Nat Rev Immunol. 2020;20(9):515&#x2010;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388427</ArticleId><ArticleId IdType="pubmed">32728221</ArticleId></ArticleIdList></Reference><Reference><Citation>Badawy MA, Yasseen BA, El&#x2010;Messiery RM, et&#xa0;al. Neutrophil&#x2010;mediated oxidative stress and albumin structural damage predict COVID&#x2010;19&#x2010;associated mortality. Elife. 2021;10:e69417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8641949</ArticleId><ArticleId IdType="pubmed">34821549</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et&#xa0;al. Diverse functional autoantibodies in patients with COVID&#x2010;19. Nature. 2021;595(7866):283&#x2010;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Caricchio R, Casanova JL, et&#xa0;al. The intersection of COVID&#x2010;19 and autoimmunity. J Clin Invest. 2021;131(24):e154886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670833</ArticleId><ArticleId IdType="pubmed">34710063</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, et&#xa0;al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID&#x2010;19): a prospective cohort study. Clin Infect Dis. 2022;74(7):1191&#x2010;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreye J, Reincke SM, Kornau HC, et&#xa0;al. A therapeutic non&#x2010;self&#x2010;reactive SARS&#x2010;CoV&#x2010;2 antibody protects from lung pathology in a COVID&#x2010;19 hamster model. Cell. 2020;183(4):1058&#x2010;1069. e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510528</ArticleId><ArticleId IdType="pubmed">33058755</ArticleId></ArticleIdList></Reference><Reference><Citation>Putry BO, Khairunnisa N, Balga HM, et&#xa0;al. Can SARS&#x2010;CoV&#x2010;2 trigger new onset of autoimmune disease in adults? A case&#x2010;based review. Heliyon. 2022;8(11):e11328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9622433</ArticleId><ArticleId IdType="pubmed">36338884</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos&#x2010;Casals M, Brito&#x2010;Zer&#xf3;n P, Mariette X. Systemic and organ&#x2010;specific immune&#x2010;related manifestations of COVID&#x2010;19. Nat Rev Rheumatol. 2021;17(6):315&#x2010;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8072739</ArticleId><ArticleId IdType="pubmed">33903743</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID&#x2010;19. Nat Rev Rheumatol. 2020;16(8):413&#x2010;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271827</ArticleId><ArticleId IdType="pubmed">32499548</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P, Casari G, Townsend L, et&#xa0;al. Studying severe long COVID to understand post&#x2010;infectious disorders beyond COVID&#x2010;19. Nat Med. 2022;28(5):879&#x2010;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">35383311</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Julg B, Mohandas S, Bradfute SB. Viral persistence, reactivation, and mechanisms of long COVID. Elife. 2023;12:e86015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10159620</ArticleId><ArticleId IdType="pubmed">37140960</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, et&#xa0;al. Postacute COVID&#x2010;19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163(2):495&#x2010;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>He ST, Wu K, Cheng Z, et&#xa0;al. Long COVID: the latest manifestations, mechanisms, and potential therapeutic interventions. MedComm. 2022;3(4):e196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9732402</ArticleId><ArticleId IdType="pubmed">36514781</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgenlander WR, Henson SN, Monaco DR, et&#xa0;al. Antibody responses to endemic coronaviruses modulate COVID&#x2010;19 convalescent plasma functionality. J Clin Invest. 2021;131(7):e146927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011893</ArticleId><ArticleId IdType="pubmed">33571169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaveri SV, Mouthon L, Kazatchkine MD. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J Neurol Neurosurg Psychiatry. 1994;57(l):6&#x2010;8. Suppl. Supp.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1016714</ArticleId><ArticleId IdType="pubmed">7964857</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabbani G, Ahn SN. Structure, enzymatic activities, glycation and therapeutic potential of human serum albumin: a natural cargo. Int J Biol Macromol. 2019;123:979&#x2010;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">30439428</ArticleId></ArticleIdList></Reference><Reference><Citation>Violi F, Ceccarelli G, Loffredo L, et&#xa0;al. Albumin supplementation dampens hypercoagulability in COVID&#x2010;19: a preliminary report. Thromb Haemost. 2021;121(1):102&#x2010;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869060</ArticleId><ArticleId IdType="pubmed">33368057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayry J, Kaveri SV. Kill 'Em All: efgartigimod immunotherapy for autoimmune diseases. Trends Pharmacol Sci. 2018;39(11):919&#x2010;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">30201270</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumberg LJ, Humphries JE, Jones SD, et&#xa0;al. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex&#x2010;mediated immune responses. Sci Adv. 2019;5(12):eaax9586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6920022</ArticleId><ArticleId IdType="pubmed">31897428</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddur MS, Lacroix&#x2010;Desmazes S, Dimitrov JD, Kazatchkine MD, Bayry J, Kaveri SV. Natural antibodies: from first&#x2010;line defense against pathogens to perpetual immune homeostasis. Clin Rev Allergy Immunol. 2020;58(2):213&#x2010;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">31161341</ArticleId></ArticleIdList></Reference><Reference><Citation>Graeter S, Simon HU, von Gunten S. Granulocyte death mediated by specific antibodies in intravenous immunoglobulin (IVIG). Pharmacol Res. 2020;154:104168.</Citation><ArticleIdList><ArticleId IdType="pubmed">30738127</ArticleId></ArticleIdList></Reference><Reference><Citation>Danieli MG, Piga MA, Paladini A, et&#xa0;al. Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease. Scand J Immunol. 2021;94(5):e13101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646640</ArticleId><ArticleId IdType="pubmed">34940980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann JHO, Enk AH. High&#x2010;dose intravenous immunoglobulin in skin autoimmune disease. Front Immunol. 2019;10:1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579842</ArticleId><ArticleId IdType="pubmed">31244821</ArticleId></ArticleIdList></Reference><Reference><Citation>Querol L, Lleix&#xe0; C. Novel immunological and therapeutic insights in Guillain&#x2010;Barr&#xe9; Syndrome and CIDP. Neurotherapeutics. 2021;18(4):2222&#x2010;2235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8455117</ArticleId><ArticleId IdType="pubmed">34549385</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;nemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology&#x2013;mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80&#x2010;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">25561275</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttmann M, Kaveri S, Hartung HP. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends Pharmacol Sci. 2013;34(8):445&#x2010;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">23791035</ArticleId></ArticleIdList></Reference><Reference><Citation>Noval Rivas M, Porritt RA, Cheng MH, Bahar I, Arditi M. Multisystem inflammatory syndrome in children and long COVID: the SARS&#x2010;CoV&#x2010;2 viral superantigen hypothesis. Front Immunol. 2022;13:941009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9300823</ArticleId><ArticleId IdType="pubmed">35874696</ArticleId></ArticleIdList></Reference><Reference><Citation>Seg&#xfa;&#x2010;Verg&#xe9;s C, Ca&#xf1;o S, Calder&#xf3;n&#x2010;G&#xf3;mez E, et&#xa0;al. Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system. Front Immunol. 2022;13:901872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9563374</ArticleId><ArticleId IdType="pubmed">36248801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kano Y, Inaoka M, Sakuma K, Shiohara T. Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug&#x2010;induced hypersensitivity syndrome. Toxicology. 2005;209(2):165&#x2010;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767030</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC, Bitzogli K, Alexopoulos H, Anti&#x2010;SARS&#x2010;CoV&#x2010;2 antibodies within IVIg preparations: cross&#x2010;reactivities with seasonal coronaviruses, natural autoimmunity, and therapeutic implications. Front Immunol. 2021;12:627285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7925824</ArticleId><ArticleId IdType="pubmed">33679770</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk A, Covini&#x2010;Souris C, Kuehnel D, De Mey C, R&#xf6;misch J, Schmidt T. SARS&#x2010;CoV&#x2010;2 neutralization in convalescent plasma and commercial lots of plasma&#x2010;derived immunoglobulin. BioDrugs. 2022;36(1):41&#x2010;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8628143</ArticleId><ArticleId IdType="pubmed">34843105</ArticleId></ArticleIdList></Reference><Reference><Citation>Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta&#x2010;analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599&#x2010;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">16940336</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner MJ, Bruno KA, Klassen SA, et&#xa0;al. Safety update: cOVID&#x2010;19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020;95(9):1888&#x2010;1897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7368917</ArticleId><ArticleId IdType="pubmed">32861333</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloch EM, Shoham S, Casadevall A, et&#xa0;al. Deployment of convalescent plasma for the prevention and treatment of COVID&#x2010;19. J Clin Invest. 2020;130(6):2757&#x2010;2765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7259988</ArticleId><ArticleId IdType="pubmed">32254064</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobian AAR, Shaz BH. Earlier the better: convalescent plasma. Blood. 2020;136(6):652&#x2010;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7414595</ArticleId><ArticleId IdType="pubmed">32761223</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloch EM, Goel R, Wendel S, et&#xa0;al. Guidance for the procurement of COVID&#x2010;19 convalescent plasma: differences between high&#x2010; and low&#x2010;middle&#x2010;income countries. Vox Sang. 2021;116(1):18&#x2010;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323328</ArticleId><ArticleId IdType="pubmed">32533868</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohn CS, Estcourt L, Grossman BJ, et&#xa0;al. COVID&#x2010;19 convalescent plasma: interim recommendations from the AABB. Transfusion. 2021;61(4):1313&#x2010;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014606</ArticleId><ArticleId IdType="pubmed">33586160</ArticleId></ArticleIdList></Reference><Reference><Citation>Huygens S, Hofsink Q, Nijhof IS, et&#xa0;al. Hyperimmune globulin for severely immunocompromised patients hospitalized with coronavirus disease 2019: a randomized, controlled trial. J Infect Dis. 2023;227(2):206&#x2010;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384649</ArticleId><ArticleId IdType="pubmed">35921542</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali S, Uddin SM, Shalim E, et&#xa0;al. Hyperimmune anti&#x2010;COVID&#x2010;19 IVIG (C&#x2010;IVIG) treatment in severe and critical COVID&#x2010;19 patients: a phase I/II randomized control trial. EClinicalMedicine. 2021;36:100926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8177439</ArticleId><ArticleId IdType="pubmed">34109306</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Chen S, Gan ES, Ooi EE. Impact of immune enhancement on Covid&#x2010;19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine. 2020;55:102768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161485</ArticleId><ArticleId IdType="pubmed">32344202</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster R, P&#xe9;rez Marc G, Wappner D, et&#xa0;al. Early high&#x2010;titer plasma therapy to prevent severe covid&#x2010;19 in older adults. N Engl J Med. 2021;384(7):610&#x2010;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7793608</ArticleId><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor PC, Adams AC, Hufford MM, et&#xa0;al. Neutralizing monoclonal antibodies for treatment of COVID&#x2010;19. Nat Rev Immunol. 2021;21(6):382&#x2010;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054133</ArticleId><ArticleId IdType="pubmed">33875867</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Sempowski GD, Saunders KO, Acharya P, Haynes BF. SARS&#x2010;CoV&#x2010;2 neutralizing antibodies for COVID&#x2010;19 prevention and treatment. Annu Rev Med. 2022;73:1&#x2010;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">34428080</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonovich VA, Burgos Pratx LD, Scibona P, et&#xa0;al. A randomized trial of convalescent plasma in covid&#x2010;19 severe pneumonia. N Engl J Med. 2021;384(7):619&#x2010;629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7722692</ArticleId><ArticleId IdType="pubmed">33232588</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner MJ, Carter RE, Senefeld JW, et&#xa0;al. Convalescent plasma antibody levels and the risk of death from covid&#x2010;19. N Engl J Med. 2021;384(11):1015&#x2010;1027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821984</ArticleId><ArticleId IdType="pubmed">33523609</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donnell MR, Grinsztejn B, Cummings MJ, et&#xa0;al. A randomized double&#x2010;blind controlled trial of convalescent plasma in adults with severe COVID&#x2010;19. J Clin Invest. 2021;131(13):e150646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8245169</ArticleId><ArticleId IdType="pubmed">33974559</ArticleId></ArticleIdList></Reference><Reference><Citation>Alemany A, Millat&#x2010;Martinez P, Corbacho&#x2010;Monn&#xe9; M, et&#xa0;al. High&#x2010;titre methylene blue&#x2010;treated convalescent plasma as an early treatment for outpatients with COVID&#x2010;19: a randomised, placebo&#x2010;controlled trial. Lancet Respir Med. 2022;10(3):278&#x2010;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828369</ArticleId><ArticleId IdType="pubmed">35150610</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile A, Ju&#xe1;rez MDV, Romero Bollon L, et&#xa0;al. Comparison of epidemiologic and clinical COVID&#x2010;19 profiles in children in argentina, during circulation of original and variant (alpha, gamma and lambda) strains. Pediatr Infect Dis J. 2023;42(2):136&#x2010;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9838605</ArticleId><ArticleId IdType="pubmed">36638400</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention. COVID Data Tracker.
; 2023. Accessed August 23, 2023. https://covid.cdc.gov/covid&#x2010;data&#x2010;tracker/#variant&#x2010;proportions
</Citation></Reference><Reference><Citation>Volz E, Mishra S, Chand M, et&#xa0;al. Assessing transmissibility of SARS&#x2010;CoV&#x2010;2 lineage B.1.1.7 in England. Nature. 2021;593(7858):266&#x2010;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">33767447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton FW, Lee T, Arnold DT, Lilford R, Hemming K. Is convalescent plasma futile in COVID&#x2010;19? A Bayesian re&#x2010;analysis of the RECOVERY randomized controlled trial. Int J Infect Dis. 2021;109:114&#x2010;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8214317</ArticleId><ArticleId IdType="pubmed">34157385</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization
. COVID&#x2010;19, 2020. Accessed March 26, 2023. https://www.who.int/emergencies/emergency&#x2010;events/item/coronavirus&#x2010;disease
</Citation></Reference><Reference><Citation>Somekh I, Stein M, Karakis I, Sim&#xf5;es EAF, Somekh E. Characteristics of SARS&#x2010;CoV&#x2010;2 infections in Israeli children during the circulation of different SARS&#x2010;CoV&#x2010;2 variants. JAMA Netw Open. 2021;4(9):e2124343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8424472</ArticleId><ArticleId IdType="pubmed">34491353</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozer EA, Simons LM, Adewumi OM, et&#xa0;al. Multiple expansions of globally uncommon SARS&#x2010;CoV&#x2010;2 lineages in Nigeria. Nat Commun. 2022;13(1):688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8813984</ArticleId><ArticleId IdType="pubmed">35115515</ArticleId></ArticleIdList></Reference><Reference><Citation>
GISAID
. Tracking of hCoV&#x2010;19 Variants. 2023. Accessed March 26, 2023. https://gisaid.org/hcov19&#x2010;variants/
</Citation></Reference><Reference><Citation>Torres C, Mojsiejczuk L, Acu&#xf1;a D, et&#xa0;al. Cost&#x2010;effective method to perform SARS&#x2010;CoV&#x2010;2 variant surveillance: detection of alpha, gamma, lambda, delta, epsilon, and zeta in Argentina. Front Med (Lausanne). 2021;8:755463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8703000</ArticleId><ArticleId IdType="pubmed">34957143</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehman Z, Umair M, Ikram A, Fahim A, Salman M. Footprints of SARS&#x2010;CoV&#x2010;2 genome diversity in Pakistan, 2020&#x2013;2021. Virol Sin. 2022;37(1):153&#x2010;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8832386</ArticleId><ArticleId IdType="pubmed">35234624</ArticleId></ArticleIdList></Reference><Reference><Citation>ACTIV&#x2010;3/TICO LY&#x2010;CoV555 Study Group , Lundgren JD, Grund B, Barkauskas CE, et&#xa0;al. A neutralizing monoclonal antibody for hospitalized patients with covid&#x2010;19. N Engl J Med. 2021;384(10):905&#x2010;914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781100</ArticleId><ArticleId IdType="pubmed">33356051</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin DO, Brennan&#x2010;Rieder D, Ngo B, et&#xa0;al. The importance of understanding the stages of COVID&#x2010;19 in treatment and trials. AIDS Rev. 2021;23(1):40&#x2010;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">33556957</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibeeb S, Ajaj I, Al&#x2010;Jighefee H, Abdallah AM. Effectiveness of convalescent plasma therapy in COVID&#x2010;19 patients with hematological malignancies: a systematic review. Hematol Rep. 2022;14(4):377&#x2010;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9778836</ArticleId><ArticleId IdType="pubmed">36547236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunze KL, Johnson PW, van Helmond N, et&#xa0;al. Mortality in individuals treated with COVID&#x2010;19 convalescent plasma varies with the geographic provenance of donors. Nat Commun. 2021;12(1):4864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357797</ArticleId><ArticleId IdType="pubmed">34381030</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et&#xa0;al. Autoantibodies against type I IFNs in patients with life&#x2010;threatening COVID&#x2010;19. Science. 2020;370(6515):eabd4585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Yuan Q, Wang H, et&#xa0;al. Antibody responses to SARS&#x2010;CoV&#x2010;2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2027&#x2010;2034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184337</ArticleId><ArticleId IdType="pubmed">32221519</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang NY, Pang AS, Chow VT, Wang DY. Understanding neutralising antibodies against SARS&#x2010;CoV&#x2010;2 and their implications in clinical practice. Mil Med Res. 2021;8(1):47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8405719</ArticleId><ArticleId IdType="pubmed">34465396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali S, Uddin SM, Ali A, et&#xa0;al. Production of hyperimmune anti&#x2010;SARS&#x2010;CoV&#x2010;2 intravenous immunoglobulin from pooled COVID&#x2010;19 convalescent plasma. Immunotherapy. 2021;13(5):397&#x2010;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7871744</ArticleId><ArticleId IdType="pubmed">33557591</ArticleId></ArticleIdList></Reference><Reference><Citation>Katragkou A, Roilides E, Walsh TJ. Role of immunoglobulin therapy to prevent and treat infections. Manag Infect Immunocompromised Host. 2018:339&#x2010;358.</Citation></Reference><Reference><Citation>Nguyen AA, Habiballah SB, Platt CD, et&#xa0;al. Immunoglobulins in the treatment of COVID&#x2010;19 infection: proceed with caution!. Clin Immunol. 2020;216:108459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211658</ArticleId><ArticleId IdType="pubmed">32418917</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et&#xa0;al. Clinical course and risk factors for mortality of adult inpatients with COVID&#x2010;19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054&#x2010;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazeraud A, Jamme M, Mancusi RL, et&#xa0;al. Intravenous immunoglobulins in patients with COVID&#x2010;19&#x2010;associated moderate&#x2010;to&#x2010;severe acute respiratory distress syndrome (ICAR): multicentre, double&#x2010;blind, placebo&#x2010;controlled, phase 3 trial. Lancet Respir Med. 2022;10(2):158&#x2010;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8585489</ArticleId><ArticleId IdType="pubmed">34774185</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Cao S, Dong H, et&#xa0;al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID&#x2010;19. J Infect. 2020;81(2):318&#x2010;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151471</ArticleId><ArticleId IdType="pubmed">32283154</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Z, Feng Y, Zhong L, et&#xa0;al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID&#x2010;19: a multicenter retrospective cohort study. Clin Transl Immunol. 2020;9(10):e1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7557105</ArticleId><ArticleId IdType="pubmed">33082954</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Chen Y, Li R, et&#xa0;al. Intravenous immunoglobulin treatment for patients with severe COVID&#x2010;19: a retrospective multicentre study. Clin Microbiol Infect. 2021;27(10):1488&#x2010;1493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8131555</ArticleId><ArticleId IdType="pubmed">34020032</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal R, Dewan A, Pandey A, Trehan N, Majid MA. Efficacy of high&#x2010;dose intravenous immunoglobulin in severe and critical COVID&#x2010;19: a retrospective cohort study. Int Immunopharmacol. 2022;106:108615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825318</ArticleId><ArticleId IdType="pubmed">35168081</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Xie J, Wu W, et&#xa0;al. Intravenous immunoglobulin therapy for critically ill COVID&#x2010;19 patients with different inflammatory phenotypes: a multicenter, retrospective study. Front Immunol. 2021;12:738532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828477</ArticleId><ArticleId IdType="pubmed">35154067</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmel T, Kraft F, Haberl H, et&#xa0;al. Intravenous IgM&#x2010;enriched immunoglobulins in critical COVID&#x2010;19: a multicentre propensity&#x2010;weighted cohort study. Crit Care. 2022;26(1):204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9260992</ArticleId><ArticleId IdType="pubmed">35799196</ArticleId></ArticleIdList></Reference><Reference><Citation>Son MBF, Murray N, Friedman K, et&#xa0;al. Multisystem inflammatory syndrome in children&#x2014;initial therapy and outcomes. N Engl J Med;385(1):23&#x2010;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220972</ArticleId><ArticleId IdType="pubmed">34133855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouldali N, Toubiana J, Antona D, et&#xa0;al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA. 2021;325(9):855&#x2010;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7851757</ArticleId><ArticleId IdType="pubmed">33523115</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson JS, Thornton AC, Ainger T, Garvy BA. Long&#x2010;term high&#x2010;dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms. Front Immunol. 2022;13:1033651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9932260</ArticleId><ArticleId IdType="pubmed">36818469</ArticleId></ArticleIdList></Reference><Reference><Citation>Oaklander AL, Mills AJ, Kelley M, et&#xa0;al. Peripheral neuropathy evaluations of patients with prolonged long COVID. Neurol Neuroimmunol Neuroinflamm. 2022;9(3):e1146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889896</ArticleId><ArticleId IdType="pubmed">35232750</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt AA, Dargham SR, Chemaitelly H, et&#xa0;al. Severity of illness in persons infected with the SARS&#x2010;CoV&#x2010;2 delta variant vs beta variant in Qatar. JAMA Intern Med. 2022;182(2):197&#x2010;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8696690</ArticleId><ArticleId IdType="pubmed">34935861</ArticleId></ArticleIdList></Reference><Reference><Citation>Relan P, Motaze NV, Kothari K, et&#xa0;al. Severity and outcomes of Omicron variant of SARS&#x2010;CoV&#x2010;2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis. BMJ Glob Health. 2023;8(7):e012328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10347449</ArticleId><ArticleId IdType="pubmed">37419502</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Wei&#xdf;m&#xfc;ller S, Bohl&#xe4;nder F, et&#xa0;al. The dual role of a polyvalent IgM/IgA&#x2010;enriched immunoglobulin preparation in activating and inhibiting the complement system. Biomedicines. 2021;9(7):817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8301464</ArticleId><ArticleId IdType="pubmed">34356880</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AS, Fatemi R, Winlow W. SARS&#x2010;CoV&#x2010;2 bound human serum albumin and systemic septic shock. Front Cardiovasc Med. 2020;7:153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7498713</ArticleId><ArticleId IdType="pubmed">33088822</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois MJ, Orellana&#x2010;Jimenez C, Melot C, et&#xa0;al. Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. Crit Care Med. 2006;34(10):2536&#x2010;2540.</Citation><ArticleIdList><ArticleId IdType="pubmed">16915107</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman ST, Rowley AH. Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol. 2015;11(8):475&#x2010;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">25907703</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris SB, Schwartz NG, Patel P, et&#xa0;al. Case series of multisystem inflammatory syndrome in adults associated with SARS&#x2010;CoV&#x2010;2 infection&#x2014;United Kingdom and United States. MMWR Morb Mortal Wkly Rep. 2020;69(40):1450&#x2010;1456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7561225</ArticleId><ArticleId IdType="pubmed">33031361</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Institutes of Health
. Therapeutic management of hospitalized pediatric patients with multisystem inflammatory syndrome in Children (MIS&#x2010;C) (with discussion on multisystem inflammatory syndrome in adults [MIS&#x2010;A]). Accessed March 26, 2023. https://www.covid19treatmentguidelines.nih.gov/management/clinical&#x2010;management&#x2010;of&#x2010;children/hospitalized&#x2010;pediatric&#x2010;patients&#x2013;therapeutic&#x2010;management&#x2010;of&#x2010;mis&#x2010;c/;2022
</Citation></Reference><Reference><Citation>Fukui S, Seki M, Minami T, et&#xa0;al. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial. Pediatr Rheumatol Online J. 2021;19(1):107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8254926</ArticleId><ArticleId IdType="pubmed">34217297</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz U, Shoenfeld Y, Zandman&#x2010;Goddard G. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off&#x2010; label use in autoimmune diseases. Curr Pharm Des. 2011;17(29):3166&#x2010;3175.</Citation><ArticleIdList><ArticleId IdType="pubmed">21864262</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung YM, Chen HY, Wei CJ, et&#xa0;al. Risk of autoimmune diseases in patients with COVID&#x2010;19: a retrospective cohort study. EClinicalMedicine. 2023;56:101783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830133</ArticleId><ArticleId IdType="pubmed">36643619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobasheri L, Nasirpour MH, Masoumi E, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 triggering autoimmune diseases. Cytokine. 2022;154:155873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8979824</ArticleId><ArticleId IdType="pubmed">35461172</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal R, Joshi A, Bhadada SK, et&#xa0;al. Endocrine follow&#x2010;up during post&#x2010;acute COVID&#x2010;19: practical recommendations based on available clinical evidence. Endocr Pract. 2022;28(4):425&#x2010;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8832848</ArticleId><ArticleId IdType="pubmed">35158058</ArticleId></ArticleIdList></Reference><Reference><Citation>Farajzadeh S, Khalili M, Dehghani S, et&#xa0;al. Top 10 acral skin manifestations associated with COVID&#x2010;19: a scoping review. Dermatol Ther. 2021;34(6):e15157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646918</ArticleId><ArticleId IdType="pubmed">34628708</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhach O, Meyer B, Eckerle I. SARS&#x2010;CoV&#x2010;2 viral load and shedding kinetics. Nat Rev Microbiol. 2023;21(3):147&#x2010;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9716513</ArticleId><ArticleId IdType="pubmed">36460930</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et&#xa0;al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nat Med. 2021;27(4):601&#x2010;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>
The National Institute for Health, Care Excellence. COVID&#x2010;19 rapid guidelines: managing the long&#x2010;term effects of COVID&#x2010;19; 2021. Accessed March 26, 2023. https://www.nice.org.uk/guidance/ng188
</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Veerdonk FL, Giamarellos&#x2010;Bourboulis E, Pickkers P, et&#xa0;al. A guide to immunotherapy for COVID&#x2010;19. Nat Med. 2022;28(1):39&#x2010;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">35064248</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization
. Report of the WHO&#x2010;China joint mission on coronavirus disease 2019 (COVID&#x2010;19); 2020. Accessed March 26, 2023. https://www.who.int/docs/default&#x2010;source/coronaviruse/who&#x2010;china&#x2010;joint&#x2010;mission&#x2010;on&#x2010;covid&#x2010;19&#x2010;final&#x2010;report.pdf
</Citation></Reference><Reference><Citation>
Centre for Evidence&#x2010;based Medicine. Oxford Centre for Evidence&#x2010;Based Medicine: Levels of Evidence;  (March 2009); 2009. Accessed August 23, 2023. https://www.cebm.ox.ac.uk/resources/levels&#x2010;of&#x2010;evidence/oxford&#x2010;centre&#x2010;for&#x2010;evidence&#x2010;based&#x2010;medicine&#x2010;levels&#x2010;of&#x2010;evidence&#x2010;march&#x2010;2009
</Citation></Reference><Reference><Citation>Kloypan C, Saesong M, Sangsuemoon J, Chantharit P, Mongkhon P. CONVALESCENT plasma for COVID&#x2010;19: a meta&#x2010;analysis of clinical trials and real&#x2010;world evidence. Eur J Clin Invest. 2021;51(11):e13663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420367</ArticleId><ArticleId IdType="pubmed">34375445</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Xu Y, He H, et&#xa0;al. A potentially effective treatment for COVID&#x2010;19: a systematic review and meta&#x2010;analysis of convalescent plasma therapy in treating severe infectious disease. Int J Infect Dis. 2020;98:334&#x2010;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334933</ArticleId><ArticleId IdType="pubmed">32634589</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng HT, Rhind SG, Beckett A. Convalescent plasma for the prevention and treatment of COVID&#x2010;19: a systematic review and quantitative analysis. JMIR Public Health Surveill. 2021;7(4):e25500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8245055</ArticleId><ArticleId IdType="pubmed">33825689</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld JW, Franchini M, Mengoli C, et&#xa0;al. COVID&#x2010;19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta&#x2010;analysis. JAMA Netw Open. 2023;6(1):e2250647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9857047</ArticleId><ArticleId IdType="pubmed">36633846</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemieniuk RA, Bartoszko JJ, D&#xed;az Martinez JP, et&#xa0;al. Antibody and cellular therapies for treatment of covid&#x2010;19: a living systematic review and network meta&#x2010;analysis. BMJ. 2021;374:n2231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8459162</ArticleId><ArticleId IdType="pubmed">34556486</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Heybati K, Ramaraju HB, et&#xa0;al. Differential efficacy and safety of anti&#x2010;SARS&#x2010;CoV&#x2010;2 antibody therapies for the management of COVID&#x2010;19: a systematic review and network meta&#x2010;analysis. Infection. 2023;51(1):21&#x2010;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016212</ArticleId><ArticleId IdType="pubmed">35438413</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Li T, Wang Y, Tran C, Zhao S, Ao G. Monoclonal antibody therapy improves severity and mortality of COVID&#x2010;19 in organ transplant recipients: a meta&#x2010;analysis. J Infect. 2022;85(4):436&#x2010;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9247112</ArticleId><ArticleId IdType="pubmed">35788012</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Zhang Y, Lu L, et&#xa0;al. Benefits of high&#x2010;dose intravenous immunoglobulin on mortality in patients with severe COVID&#x2010;19: an updated systematic review and meta&#x2010;analysis. Front Immunol. 2023;14:1116738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9900022</ArticleId><ArticleId IdType="pubmed">36756131</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang HR, Cheng X, Li Y, et&#xa0;al. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID&#x2010;19): a meta&#x2010;analysis. Int Immunopharmacol. 2021;96:107732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084608</ArticleId><ArticleId IdType="pubmed">34162133</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Zhao S, Tang Y, et&#xa0;al. Potentially effective drugs for the treatment of COVID&#x2010;19 or MIS&#x2010;C in children: a systematic review. Eur J Pediatr. 2022;181(5):2135&#x2010;2146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861482</ArticleId><ArticleId IdType="pubmed">35192051</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence&#x2010;based medicine. Plast Reconstr Surg. 2011;128(1):305&#x2010;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124652</ArticleId><ArticleId IdType="pubmed">21701348</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharbharan A, Jordans CCE, GeurtsvanKessel C, et&#xa0;al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS&#x2010;CoV&#x2010;2 infection. Nat Commun. 2021;12(1):3189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8160346</ArticleId><ArticleId IdType="pubmed">34045486</ArticleId></ArticleIdList></Reference><Reference><Citation>Benner SE, Patel EU, Laeyendecker O, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 antibody avidity responses in COVID&#x2010;19 patients and convalescent plasma donors. J Infect Dis. 2020;222(12):1974&#x2010;1984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499592</ArticleId><ArticleId IdType="pubmed">32910175</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobian AAR, Cohn CS, Shaz BH. COVID&#x2010;19 convalescent plasma. Blood. 2022;140(3):196&#x2010;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8548835</ArticleId><ArticleId IdType="pubmed">34695186</ArticleId></ArticleIdList></Reference><Reference><Citation>Dispinseri S, Secchi M, Pirillo MF, et&#xa0;al. Neutralizing antibody responses to SARS&#x2010;CoV&#x2010;2 in symptomatic COVID&#x2010;19 is persistent and critical for survival. Nat Commun. 2021;12(1):2670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113594</ArticleId><ArticleId IdType="pubmed">33976165</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Mateus J, Coelho CH, et&#xa0;al. Humoral and cellular immune memory to four COVID&#x2010;19 vaccines. Cell. 2022;185(14):2434&#x2010;2451. e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9135677</ArticleId><ArticleId IdType="pubmed">35764089</ArticleId></ArticleIdList></Reference><Reference><Citation>Caillard S, Benotmane I, Gautier Vargas G, Perrin P, Fafi&#x2010;Kremer S. SARS&#x2010;CoV&#x2010;2 viral dynamics in immunocompromised patients. Am J Transplant. 2021;21(4):1667&#x2010;1669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675471</ArticleId><ArticleId IdType="pubmed">33048424</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang K, Wu X, Luo Y, et&#xa0;al. Meta&#x2010;analysis of immunologic response after COVID&#x2010;19 mRNA vaccination in solid organ transplant recipients. J Infect. 2022;84(5):e73&#x2010;e75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8857776</ArticleId><ArticleId IdType="pubmed">35192894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertuccio P, Degli Antoni M, Minisci D, et&#xa0;al. The impact of early therapies for COVID&#x2010;19 on death, hospitalization and persisting symptoms: a retrospective study. Infection. 2023:1&#x2010;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10079146</ArticleId><ArticleId IdType="pubmed">37024626</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilardin L, Bayry J, Kaveri SV. Intravenous immunoglobulin as clinical immune&#x2010;modulating therapy. Cmaj. 2015;187(4):257&#x2010;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4347774</ArticleId><ArticleId IdType="pubmed">25667260</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>